Endocannabinoid system in sexual motivational processes: Is it a novel therapeutic horizon?

详细信息    查看全文

• 作者：Renata Androvicova^a ; ^b ; Jiri Horacek^a ; ^b ; Tibor Stark^c ; Filippo Drago^d ; Vincenzo Micale^d ; ^e ; ^{vincenzomicale@inwind.it}
• 关键词：Endocannabinoids ; Δ9-THC ; Cannabinoid CB1 receptor ; Sexual behavior
• 刊名：Pharmacological Research
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：115
• 期：Complete
• 页码：200-208
• 全文大小：1021 K
• 卷排序：115

文摘

The endocannabinoid system (ECS), which is composed of the cannabinoid receptors types 1 and 2 (CB1 and CB2) for marijuana’s psychoactive ingredient Δ9-tetrahydrocannabinol (Δ9-THC), the endogenous ligands (AEA and 2-AG) and the enzymatic systems involved in their biosynthesis and degradation, recently emerged as important modulator of emotional and non-emotional behaviors. For centuries, in addition to its recreational actions, several contradictory claims regarding the effects of Cannabis use in sexual functioning and behavior (e.g. aphrodisiac vs anti-aphrodisiac) of both sexes have been accumulated. The identification of Δ9-THC and later on, the discovery of the ECS have opened a potential therapeutic target for sexual dysfunctions, given the partial efficacy of current pharmacological treatment. In agreement with the bidirectional modulation induced by cannabinoids on several behavioral responses, the endogenous cannabinoid AEA elicited biphasic effects on sexual behavior as well. The present article reviews current available knowledge on herbal, synthetic and endogenous cannabinoids with respect to the modulation of several aspects of sexuality in preclinical and human studies, highlighting their therapeutic potential.